A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib

Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased over...

Descripción completa

Detalles Bibliográficos
Autores principales: Gabriel, Joseph Gabriel, Kapila, Aaysha, Gonzalez-Estrada, Alexei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446100/
https://www.ncbi.nlm.nih.gov/pubmed/28589155
http://dx.doi.org/10.1177/2324709617711463
_version_ 1783239007388303360
author Gabriel, Joseph Gabriel
Kapila, Aaysha
Gonzalez-Estrada, Alexei
author_facet Gabriel, Joseph Gabriel
Kapila, Aaysha
Gonzalez-Estrada, Alexei
author_sort Gabriel, Joseph Gabriel
collection PubMed
description Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased overall survival and life-threatening serious adverse events. The following is an unfortunate case of a grade III adverse skin reaction secondary to idelalisib with the likely complication of methicillin-resistant Staphylococcus aureus bacteremia.
format Online
Article
Text
id pubmed-5446100
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-54461002017-06-06 A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib Gabriel, Joseph Gabriel Kapila, Aaysha Gonzalez-Estrada, Alexei J Investig Med High Impact Case Rep Case Report Phosphatidylinositol 3-kinase δ (PIK3δ) is a tyrosine kinase essential for B cell survival, making it an important target in the treatment of chronic lymphocytic leukemia. Idelalisib is an inhibitor of PIK3δ demonstrating initial success in disease response, but is now shown to have a decreased overall survival and life-threatening serious adverse events. The following is an unfortunate case of a grade III adverse skin reaction secondary to idelalisib with the likely complication of methicillin-resistant Staphylococcus aureus bacteremia. SAGE Publications 2017-05-24 /pmc/articles/PMC5446100/ /pubmed/28589155 http://dx.doi.org/10.1177/2324709617711463 Text en © 2017 American Federation for Medical Research http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Gabriel, Joseph Gabriel
Kapila, Aaysha
Gonzalez-Estrada, Alexei
A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
title A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
title_full A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
title_fullStr A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
title_full_unstemmed A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
title_short A Severe Case of Cutaneous Adverse Drug Reaction Secondary to a Novice Drug: Idelalisib
title_sort severe case of cutaneous adverse drug reaction secondary to a novice drug: idelalisib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446100/
https://www.ncbi.nlm.nih.gov/pubmed/28589155
http://dx.doi.org/10.1177/2324709617711463
work_keys_str_mv AT gabrieljosephgabriel aseverecaseofcutaneousadversedrugreactionsecondarytoanovicedrugidelalisib
AT kapilaaaysha aseverecaseofcutaneousadversedrugreactionsecondarytoanovicedrugidelalisib
AT gonzalezestradaalexei aseverecaseofcutaneousadversedrugreactionsecondarytoanovicedrugidelalisib
AT gabrieljosephgabriel severecaseofcutaneousadversedrugreactionsecondarytoanovicedrugidelalisib
AT kapilaaaysha severecaseofcutaneousadversedrugreactionsecondarytoanovicedrugidelalisib
AT gonzalezestradaalexei severecaseofcutaneousadversedrugreactionsecondarytoanovicedrugidelalisib

Ejemplares similares